ChroMedX!
Das kann doch wirklich nicht so schwierig, das mit der clearingstelle hinzubekommen!!!
Oder ist es doch mittlerweile ein handelsstopp bei uns????
mannomann!!
Kann das jemand bestätigen oder dementieren? Denn in diesem Fall müssten wir schnellstmöglich versuchen, das bisschen verbliebenen Wert noch raus zu ziehen...
May 8, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to report on HemoPalm activities.
In early January 2018 ChroMedX announced the appointment of Lahav Gil as Chief Executive Officer and Director. Since that time Lahav has led the expansion of the Company’s development infrastructure and team to conduct a techno-commercial analysis and feasibility study for the acceleration of HemoPalm productization and path to the market.
“After investing the last 4 months into a HemoPalm “deep dive”, my team and I are in the process of transitioning the company from a technology and R&D focus into a productization focus. I sincerely appreciate the patience of our board and shareholders, in giving us the time to do the investigations, market outreach, and strategic thought process that are necessary when putting this transition into motion. In many cases during such a process, some institutional knowledge gets lost and needs to be regained. At the same time, fresh eyes and fresh thoughts enable a better understanding of the technical, user and market requirements.” said Lahav Gil, CEO & Director, ChroMedX Corp.
“Successful commercialization and innovation of medical technologies requires design and engineering that significantly enhances clinical utility and the cost of healthcare, as a system. We call this the clini-commercial application. When productizing a device like the HemoPalm, it must be designed as a holistic system with a deep understanding of the evaluation processes and the triggers for adoption by the hospital. Our HP productization strategy is to make the best product in the world for the defined clini-commercial application; critical care patients in the hospital setting. We are aiming to significantly improve on the workflow and the clinical decisions for patients in critical care, as well as improve the cost efficiencies for the hospital, while building towards a high-value strategic exit opportunity.”
When building an innovation culture it is very important to “start with the end in mind” (Steven Covey), and at the same time remain be open to unexpected insights and aha moments”
Techno-commercial activities in recent months have been geared towards building the operational tempo and innovation ecosystem in which the HemoPalm and other technologies can be accelerated towards market readiness and exit transactions. This includes building the techno-commercial team and culture, implementing infrastructure and systems, and laying out process and SOPs. This process, while seemingly slow at first, later leads to rapid productization and agility when optimizing for the application and the product feature-set.
Market Research and Analysis
In 2017 the ChroMedX development team focused on the research, development, benchmarking, modeling and validating of the core components of the HemoPalm technology. In the beginning months of 2018 the Company’s techno-commercial team has conducted in-depth market research and analysis to outline product strategy and exit requirements to define the HemoPalm feature set, path to the market, technical implementation roadmap and productization plan.
Research activities have included extensive VOC (voice-of-customer) outreach, business analysis, feasibility assessments and consultation with market leaders, industry veterans, and clinical KOLs.
Market intelligence gathered has led to the identification of key value drivers leading to adoption of the HP, which include enhancing workplace efficiencies, improving clinical decision making, preventing human error, optimizing cost of ownership, and reducing barriers to adoption.
During this process the development team has explored opportunities for additional innovation around understanding workflow bottlenecks and mitigating for human error in the ICU.
“Things like simplifying sample handling, auto calibration, inbuilt training and IT integration to name a few, demonstrate how to see the device as a holistic system serving a multiplicity of stakeholders and value drivers in the Critical Care market place. This kind of strategy enables us to envision the HemoPalm impacting larger markets and use-case environments where logistics, staff training, and process improvement are critical to patient care and hospital efficiencies.” said Lahav Gil, CEO & Director, ChroMedX Corp., “It is also very important to clearly understand the requirements of the exit partner and to “bake” them into the product system architecture.”
HemoPalm Productization
Following the undertaking of comprehensive research activities, the Company is strategizing and planning a productization roadmap that includes understanding barriers to adoption, process improvements in the ICU and reducing the total cost of ownership compared to existing solutions.
More specifically the Company has been analysing value drivers and requirements for:
· The test menu
· Design for adoption
· Process improvements in the the ICU
· Improving workflow, usability and Human Factors
· Device fleet management
· Integrating with ICU infrastructure
· Seamless integration with hospital IT systems and patient records
· Reducing the total time-to-results
· Improving and de-skilling sample handling
· Defining the exit value (commercial value) to operators in marketplace
· Scale manufacturing and logistics
· Mitigating for human error
ChroMedX News & Disclosure
Parties interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel, handheld medical devices for diagnostic testing at the patient’s bedside.
HemoPalm, the Company’s lead product is the only handheld blood analysis system which combines Blood Gases & Electrolytes with full CO-oximetry. It has a single-use cartridge/handheld reader format, providing the simplest, most rapid and accurate testing process for use in management of critical care patients. Current blood gas systems require purchase of a second device to carry out CO-oximetry measurements. In addition, HemoPalm has the ability to draw capillary blood directly from pin-prick sites into the cartridge, in addition to the commonly required, risk-associated arterial blood draws.
ChroMedX Corp. technologies are protected by the Company’s issued and pending patents, covering blood/plasma/serum collection, and processing and analysis.
Website: www.chromedx.com
Contact:
W. Clark Kent
President & Director
ChroMedX Corp.
Office. 647-872-9982 ext. 2
Ich hoffe für alle, welche hier schon eine Weile investiert sind, dass mal Licht am Tunnel in Sicht kommt und Lahav Gil dabei bleibt. Bisher leider keine Information über Verhandlungen mit Interessenten, das bedeutet für mich, dass das Produkt noch unausgereift ist.
Um hier einzusteigen sollte man besser einen anderen Reifegrad abwarten, ansonsten könnte auch Totalverlust drohen.
Erfolg wäre aber den Leidgeplagten zu gönnen. Toi, Toi, Toi
IIROC Trading Halt - CHX
Canada NewsWire
VANCOUVER, May 9, 2018
VANCOUVER, May 9, 2018 /CNW/ - The following issues have been halted by IIROC:
Company: CHROMEDX CORP
CSE Symbol: CHX
Reason: At the request of the Company Pending News
Halt Time (ET): 8:57 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
View original content: http://www.newswire.ca/en/releases/archive/May2018/09/c5805.html
IIROC Inquiries 1-877-442-4322 (Option 2) - Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.Copyright CNW Group 2018
§
May 09, 2018 – ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: CHXIF, Frankfurt: EIY2), developer of the HemoPalm Handheld Blood Analyzer Platform, is pleased to announce that it has entered into a binding Letter-of-Intent (“LOI”) to acquire Ottawa, Ontario based medtech data science company, UX Data Sciences Corp. (“UXD”).
UX Data Sciences Corp. is a private Ottawa-based medical technology and data science company developing UX-centric products and systems solutions for improving, tracking and monitoring patient compliance and medication adherence. Medication adherence refers to whether patients take their medications as prescribed, as well as whether they continue to take a prescribed medication.
In North America it is estimated that patient compliance and medication adherence is less than 50%1 which means more than half of patients/consumers are likely to improperly take or skip medications, appointments, and other treatment protocols. 125,000 unnecessary deaths are estimated to occur every year in the US due to this issue2 and adds an estimated US $290B to the US health care system3.
“We are thrilled to be a part of the opportunity that this transaction represents for the shareholders of UXD. We are confident that combining resources and consolidating management teams under the leadership of Lahav Gil will nurture innovation and accelerate product development, resulting in a shorter commercialization cycle for a benefit to all.” said Mikhail Atlas, CEO & German Kavoun, Co-Founder, UX Data Sciences Corp.
ChroMedX CEO Lahav Gil has been the Chairman and a shareholder of UX Data Sciences since September 2016. Due to this, the proposed transaction is being treated by the Company as a related party transaction and Lahav will abstain from voting or consulting on matters relating to the transaction as a member of either party. Lahav owns approximately 13.5% of the outstanding UXD shares.
“These are very exiting developments for all of us at CHX. The interactive nature of the UXD technology and the intelligence that drives it, are very unique and promise to change some of the paradigms around medication adherence. I’m really looking forward to the amalgamation of our teams and sharing infrastructure and resources to accelerate the development cycle towards upcoming pilot trials.” said Lahav Gil, CEO, ChroMedX Corp.
Under the terms of the LOI ChroMedX will acquire UXD and UXD would become a wholly-owned subsidiary of the Company. Accordingly, ChroMedX will acquire UXD’s technologies and intellectual property. The Company will acquire UXD by the issuance of common shares of the Company having a value of CAD $5,500,000. The shares issued will be calculated based on the average closing price of ChroMedX for the 45 trading days preceding the signing of the LOI and will be subject to an escrow schedule with stock being released over a 3-year period. This calculation would result in the issuance of 15,277,778 common shares bringing the Company’s issued and outstanding share total to 100,935,001. The share issuance is subject to the Company’s compliance with the filing requirements of the CSE and applicable securities laws.
ChroMedX and UXD are now working towards the completion of a definitive agreement. The parties expect that the transaction will be structured as a share exchange transaction where all of the shareholders of UXD will sell and transfer their UXD shares to ChroMedX in exchange for the issuance of the ChroMedX shares. The definitive agreement will contain the covenants and conditions set out herein and additional representations, warranties and terms that are normally included in similar transactions. Lahav will participate in the share exchange as a shareholder of UXD, on the same terms as the other shareholders of UXD.
Footnotes
1 Source: Data from The World Health Organization (2003)
2 Source: Data from AM Pharm (1989)
3 Source: NEHI (2009)
ChroMedX News & Disclosure
Parties interested in keeping abreast of latest news and updates can subscribe on the Home and News pages on the Company's website at www.ChroMedX.com
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel, handheld medical devices for diagnostic testing at the patient’s bedside.
HemoPalm, the Company’s lead product is the only handheld blood analysis system which combines Blood Gases & Electrolytes with full CO-oximetry. It has a single-use cartridge/handheld reader format, providing the simplest, most rapid and accurate testing process for use in management of critical care patients. Current blood gas systems require purchase of a second device to carry out CO-oximetry measurements. ChroMedX Corp. technologies are protected by the Company’s issued and pending patents, covering blood/plasma/serum collection, and processing and analysis.
Website: www.chromedx.com
Contact:
W. Clark Kent
President
ChroMedX Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@chromedx.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
UX Data Sciences Corp. ist ein privates Medizintechnik- und Data-Science-Unternehmen mit Sitz in Ottawa, das UX-zentrische Produkte und Systemlösungen zur Verbesserung, Verfolgung und Überwachung der Compliance und Einhaltung von Medikamenten entwickelt. Die Einhaltung der Medikamente bezieht sich darauf, ob die Patienten ihre Medikamente wie vorgeschrieben einnehmen und ob sie weiterhin ein verschriebenes Medikament einnehmen.
In Nordamerika wird geschätzt, dass die Compliance der Patienten und die Einhaltung der Medikation unter 50% liegt 1, was bedeutet, dass mehr als die Hälfte der Patienten / Konsumenten wahrscheinlich Medikamente, Termine und andere Behandlungsprotokolle falsch einnehmen oder überspringen. Schätzungen zufolge treten in den USA jedes Jahr 125.000 unnötige Todesfälle auf, was dem US-Gesundheitssystem geschätzte US $ 290 Mrd. hinzufügt3.
"Wir freuen uns, Teil der Chance zu sein, die diese Transaktion für die Aktionäre von UXD darstellt. Wir sind zuversichtlich, dass die Bündelung von Ressourcen und die Konsolidierung von Managementteams unter der Führung von Lahav Gil Innovationen fördern und die Produktentwicklung beschleunigen werden, was zu einem kürzeren Vermarktungszyklus führen wird, von dem alle profitieren werden ", sagte Mikhail Atlas, CEO & German Kavoun, Co-Founder. UX Data Sciences Corp.
Text zur Anzeige gekürzt. Gesamtbeitrag anzeigen »
vielleicht gibt es hier ja jemanden der das klarstellen kann. danke im voraus !
STRONG BUY: ChroMedX Corp.
CANADA/CSE: CHX, WKN: A12B6G
Gestern hat die Firma News veröffentlicht:
CHROMEDX REPORTS ON HEMOPALM TECHNO-COMMERCIAL ANALYSIS AND PRODUCTIZATION PLAN
[...] Zusammenfassung der News von gestern zur Produktisierung
Aktie und Kursverlauf an der CSE:
Ich habe Informationen, die nahe legen, dass die Aktie in den nächsten Tagen in Deutschland wieder handelbar sein müsste. Wie sich herausgestellt hat dürfte ein Clearstream Mitarbeiter einen kathastrophalen Fehler gemacht haben, indem er ohne Grund die Abwicklungserklärung für die Aktie entzogen hat.
Dies hat der Firma natürlich in ihrer Reputation geschadet, was auch am Kurs ersichtlich ist. Leider geben die Anwälte einer Klage gegen Clearstream keine Chance.
Trotz der Nachricht, dass der Ablauf vom Prototypen Stadium in Richtung verkaufbares Produkt im vollem Gange ist verlor die Aktie gestern an Wert.
Ich glaube, dass einige Anleger aus Deutschland ihre Aktien vom Lagerort Deutschland nach Kanada umbuchen haben lassen. Die News wurde gestern zu "Sell on Good News" genutzt, Aber ich bin davon überzeugt, dass ein Kauf der ChromedX Aktie den weitaus größeren Sinn macht als der Verkauf, für alle jenen die an der Heimatbörse in Kanada kaufen können!
Optionen
| Boardmail an "Jawizo" |
Wertpapier: Scryb Inc |